Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor
Copyright 2000 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2000
In Reply: While we agree with Dr Köhler
and colleagues that the CLASS trial supports the hypothesis that COX-2–specific
inhibitors will produce fewer ulcers and ulcer complications than conventional
NSAIDs, we disagree that the data suggest the possibility that celecoxib interferes
with healing of aspirin-induced GI mucosal lesions. A prior study1 has found that the relative risk of an ulcer complication
in aspirin users vs nonaspirin users is approximately the same as the relative
risk of an ulcer complication in aspirin users receiving celecoxib vs nonaspirin
users receiving celecoxib that we reported.
Lefkowith JB, Geis GS, Silverstein F. Safety of Celecoxib vs Other Nonsteroidal Anti-inflammatory Drugs—Reply. JAMA. 2000;284(24):3123-3124. doi:10.1001/jama.284.24.3123